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Abstract
Background: The mammalian target of rapamycin (mTOR) plays a key role in cellular growth and homeostasis. The
purpose of our present study is to investigate the expression of activated mTOR (p-mTOR) in gastric cancer
patients, their prognostic significance and the inhibition effect of RAD001 on tumor growth and to determine
whether targeted inhibition of mTOR could be a potential therapeutic strategy for gastric cancer.
Methods: The expression of p-mTOR was detected in specimens of 181 gastric cancers who underwent radical
resection (R0) by immunohistochemistry. The correlation of p-mTOR expression to clinicopathologic features and
survival of gastric cancer was studied. We also determined the inhibition effect of RAD001 on tumor growth using
BGC823 and AGS human gastric cancer cell lines.
Results: Immunostaining for p-mTOR was positive in 93 of 181 (51.4%) gastric cancers, closely correlated with
lymph node status and pTNM stage. Patients with p-mTOR positive showed significantly shorter disease-free
survival (DFS) and overall survival (OS) rates than those with p-mTOR-negative tumors in univariable analyses, and
there was a trend toward a correlation between p-mTOR expression and survival in multivariable analyses. RAD001
markedly inhibited dose-dependently proliferation of human gastric carcinoma cells by down-regulating expression
of p70s6k, p-p70s6k, C-myc, CyclinD1 and Bcl-2, up-regulating expression of P53.
Conclusions: In gastric cancer, p-mTOR is a potential therapeutic target and RAD001 was a promising treatment
agent with inducing cell cycle arrest and apoptosis by down-regulating expression of C-myc, CyclinD1 and Bcl-2,
up-regulating expression of P53.
Background
Gastric carcinoma is the fourth most common cancer
and the second leading cause of cancer-related death
worldwide, including 1 million new cases per year
throughout the world [1]. About 60% of new cases of
gastric cancer occur in eastern Asia [2], especially in
China. Surgical resection is the most effective treatment
for gastric cancer and the efficacy of chemotherapy
remains limited [3]. Many studies have indicated that
the depth of invasion and the number of metastatic
lymph nodes are the most important powerful predic-
tors of survival for gastric cancer patients [4,5]. For
example, in previous studies [6,7], we have found
positive lymph node ratio is an independent prognostic
indicator after D2 resection and intraperitoneal che-
motherapy may be beneficial to gastric cancer patients.
However, a fundamental step toward improving clinical
outcome lies in the increased understanding of the
tumor biological behavior, which may help to identify
the possible targets for individual therapy [8,9].
In recent years, molecularly based approaches for
treatment in gastric cancer has been given great con-
cern. Several articles have described some potential
molecular targets for therapy in gastric cancer, such as
epidermal growth factor receptor (EGFR) [10-13], vascu-
lar endothelial growth factor (VEGF) [14], recepteur
d’origine nantais (RON) [15].
The mammalian target of rapamycin (mTOR) is a new
potential molecular target for anticancer therapy. Its
expression has been demonstrated in various cell lines
and tumor specimens, such as liver neoplasms [16],
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and cervical cancer [19,20]. These studies showed that
mTOR expression was associated with poor clinical
prognosis. Lang et al [21]. have also observed mTOR
activation in human gastric cancer in vitro and in vivo.
They indicated mTOR is frequently activated in human
gastric cancer. Recently, an orally bioavailable derivative
of rapamycin, RAD001 (everolimus; Novartis Pharma
AG), has been developed. A phase III trial revealed
treatment with everolimus prolongs progression-free
survival in patients with metastatic renal cell carcinoma
that had progressed on other targeted therapies [22].
RAD001 has also been shown to inhibit the proliferation
of tumor cell growth in some carcinomas [23,24]. But
the role of RAD001 in gastric cancers cell is not clear.
T h ea i m so ft h i ss t u d yw e r et of u r t h e ra n a l y z et h e
relationships the mTOR expression with the prognosis
value of activated mTOR (p-mTOR), the effect of
RAD001 on the growth and cell cycle of human gastric
cancer cells in vitro and determine whether gastric can-
cer is a good candidate for target therapy with mTOR
inhibitors.
Methods
Patients studied
This retrospective study consisted of 181 patients who
underwent radical resection (R0) for histologically con-
firmed gastric carcinoma from Cancer Center of Sun
Yat-sen University between January 1997 and December
2002. All patients with histologically confirmed adeno-
carcinoma of the stomach had undergone either proxi-
mal partial gastrectomy, distal partial gastrectomy or
total gastrectomy. Ethical approval was obtained from
Sun Yat-sen University Cancer Center research ethics
committee.
Those with adequate histological material and com-
plete clinical data were eligible for inclusion. The elig-
ibility criteria also included histologically confirmed R0
resection, which was defined as no macroscopic and
microscopic residual tumor and postoperative survival
time ≥ 6 months. Patients with distant metastases and
carcinoma of gastric stump after resection for benign
d i s e a s ew e r ee x c l u d e df r o mt h es t u d y .T h er e a s o ni s
that the survival of patients with distant metastases is
often affected by many other factors, such as preopera-
tive chemotherapy or obstruction.
All patients had follow-up after surgery at 6 to 12
month intervals; the final date of follow-up was Decem-
ber 2008. Median follow up period was 50 (mean: 50.66;
range 10 to 128) months for all patients, and 74 months
(mean: 72.80; range 27 to 128) for survival. Median
duration of follow up was 40 (mean: 43.71; range 11 to
125) for patients who had tumors of p-mTOR positive
expression, and 60.5 months (mean: 58.01; range 10 to
128) for negative expression. Survival was calculated
from the date of diagnosis until the date of death or last
follow-up.
Specimen collection and Immunostaining for p-mTOR
All tumor specimens were obtained from surgically
resected gastric cancers before adjuvant therapy. Forma-
lin-fixed, paraffin-embedded tissue blocks were stored at
room temperature identified by an identification num-
ber. Five-μm-thick tissue sections were cut from the
paraffin blocks, deparaffinized in xylene, and rehydrated.
Antigenic retrieval was processed with sodium citrate.
The slides were then incubated in 0.3% H2O2 for 10
min, and blocked in 1% bovine serum albumin for 60
min followed by a rabbit monoclonal antibody specific
for p-mTOR (Phospho-mTOR, Ser2448, 49F9; Cell Sig-
naling Technology) at 4°C overnight, and then stained
with 3,3-diaminobenzidine. After visualization of immu-
noreactivity, the sections were counterstained with
hematoxylin and then mounted.
Evaluation of Immunohistochemical Staining
The immunostained sections were evaluated and tissues
from human prostate adenocarcinomas served as posi-
tive control. According to recently described criteria for
rating mTOR expression, staining intensity was deter-
mined as 0 (absent), 1 (weak), and 2 (strong) and
expression levels of the biomarkers were semiquantified
using an immunohistochemistry score (range, 0-200)
calculated by multiplying staining intensity with the per-
centage of positive tumor cells[18]. Patients with an
immunohistochemistry score of ≤ 20 were considered as
p-mTOR-negative and those with a score of > 20 as p-
mTOR-positive. All slides were independently assessed
by two independent pathologists without any knowledge
of the patients’ clinical information. When the opinions
of the two evaluators were different, agreement was
reached by careful discussion.
Cell lines and culture conditions
Human gastric cancer cell lines BGC823 and AGS
(ATCC Number: CRL-1739) which are poorly differen-
tiated were gifts from Peking University School of
Oncology (Beijing, P.R. China.) [25]. The cell lines were
maintained in RPMI 1640 medium (Invitrogen) supple-
mented with 10% fetal bovine serum (Hyclone), penicil-
lin (100 units/mL) and streptomycin (100 units/mL) at
37°C and 5% CO2 in a humidified incubator.
Cell viability assay
To analyze the effect of RAD001 on human gastric can-
cer cells, cell viability was determined by MTT assay.
RAD001 was provided by Novartis Pharma (Basel, Swit-
zerland). For the viability assay, logarithmically growing
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Page 2 of 10cells were stimulated with various doses of RAD001 (0,
5, 10, 20 and 40 μM ) .A tt h ee n do fc u l t u r ep e r i o d ,2 0
μL of tetrazolium dye 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma, USA) solu-
tion at 0.2 mg/ml in PBS was added, the optical density
at 490 nm (OD490) was determined by using an
enzyme-linked immunosorbent assay (ELISA) reader.
Mean values were calculated from triplicate cultures.
Cell cycle analysis
Cells were collected and fixed in 70% ethanol overnight
at 4°C. Cells were then washed and stained with propi-
dium iodide (PI) (Sigma) 5 μg/mL. After 30 min at
room temperature protected from light, the cells were
analysed via flow cytometry using a Becton Dickinson
FACScan.
Annexin V assay
The samples were washed with phosphate-buffered sal-
ine (PBS) and using Annexin V-fluorescein isothiocya-
nate (FITC) and PI staining for determination of
phosphatidylserine exposure on the outer plasma mem-
brane. After incubation for 30 min at room temperature
protected from light, the samples were quantified by
flow cytometry, using a Becton Dickinson FACScan.
Reverse transcription-PCR
Total RNA was extracted by using TRIzol method. RNA
was reversely transcripted using a commercially available
kit (Fermentas, USA). The mixture (25 μL total) for PCR
consisted of 0.5 μl cDNA, 0.5 U Taq DNA polymerase,
2.5 μl of 10× PCR buffer, 2.5 mM dNTP mixture, and 50
pM sense and antisense primers each. CyclinD1 and C-
m y cw e r ea n a l y z e db yf o l l o w i n gp r i m e r s :C y c l i n D 1
5’GAACAGAAGTGCGAGGAGGAG3’ and reverse pri-
mer 5’AGGCGGTAGTAGGACAGGAAG3’;C - m y c ,5 ’
CGAGCTGCTGGGAGGAGACAT3’ and 5’ AGCCGCC-
CACTTTTGACA GG3’ Actin: 5’GGCACCCAGCA-
CAATGAA 3’ and 5’ TAGAAGCATTTGCGGTGG 3’.
Cell lysate and Western blot analysis
Cells were lysed in lysis buffer and the concentration of
protein was determined by the Bradford dye method
(Bio-Rad Laboratories). Equal amounts of cell extract
were subjected to SDS-PAGE and transferred to PVDF
membrane (Bio-Rad). Western blot analyses were done
with various specific primary antibodies. Antibodies
recognizing phospho-p70S6K (Thr389), p70S6K, phos-
pho-mTOR(Ser2448), Bcl-2 and p53 were from Cell
Signaling.
Statistical analyses
The primary end point of our study was overall survi-
val (OS). It was defined as the period between the time
of surgery and death. Disease-free survival (DFS) was
the time between the time of surgery and relapse or
tumor-related death. It was analyzed as a secondary
end point. The association of p-mTOR expression with
various clinicalopathologic features was analyzed using
the chi-square test. Cumulative survival and disease-
free survival were estimated by the Kaplan-Meier
method. The log-rank test was used to evaluate the
statistical significance of differences between survival
curves. A Cox proportional hazard model (backward,
stepwise) for multivariable analysis was applied for fac-
tors that achieved significance in univariable analysis.
Statistical analysis was performed using SPSS software
(version 13 for Windows; SPSS, Chicago, IL). Differ-
ences at P < .05 were considered to be statistically
significant.
Results
Clinicopathologic features
A total of 181 patients were enrolled in this study. The
median age was 59 years (range, 23-83 years). The clini-
copathologic characteristics of the study population are
summarized in Table 1. 129 patients were male and 52
female. 77 of 181 tumors (42.5) were from the upper
stomach, 74 of 181 patients (40.9%) were from the
lower part of the stomach, and the remaining tumors
were from the middle and whole body of the stomach.
118 of 181(65.2%) patients’ tumor size were > 4 cm, and
63 (34.8%) were ≤ 4 cm. In accordance with World
Health Organization criteria, 4 of 181 tumors (2.2%)
were well differentiated, 55 of 181 tumors (30.4%) were
moderately differentiated, 116 were poorly differentiated,
and 6 were undifferentiated. Post-operative surgical
stage was classified according to the 2002 UICC/AJCC
classification [26].
129 of 181 patients (71.2%) had more advanced T
stage disease (PT3+PT4), and 137 patients (75.7%) had
lymph node metastasis. Totally patients of stage I-IV
were 26, 47, 100 and 8 cases, respectively.
p-mTOR expression in gastric cancer
Immunostaining of p-mTOR was cytoplasmatic and
partly membranous. Figure 1 shows representative
examples of p-mTOR immunostaining. The normal gas-
tric mucosa is negative for p-mTOR. Of the 181
patients, 93 (51.4%) were p-mTOR-positive tumors.
Survival analysis
Patients with p-mTOR positive gastric cancer showed
significantly shorter disease-free and overall survival
rates than those with p-mTOR negative gastric cancer
(DFS, 48.9% versus 30.1%; p = .006; OS, 51.1% versus
34.4%; p = .011; Table 2; Figure 2A, B). Univariable ana-
lysis revealed that survival time also decreased with
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Page 3 of 10higher pT classification (DFS, p = .001; OS, P = .005),
lymph node metastasis (DFS, p < .0001; OS, P = .001)
and advanced pTNM stage (DFS, p < .001; OS, P =
.001). There was no association between DFS or OS and
age, sex or tumor size.
In multivariable analysis, lymph node metastasis (DFS,
p = .018; OS, P = .038) and pT stage (DFS, p = .018;
OS, P = .046) were significant independent prognostic
factor for survival time. In addition, multivariable analy-
sis (Table 3) also indicated a trend toward a correlation
between p-mTOR expression and decreased survival,
but the trend did not reach statistical significance (DFS,
p = .059; OS, P = .070).
RAD001 inhibits proliferation and prevents p70S6K
phosphorylation
To investigate the effects of RAD001 on the prolifera-
tion of human gastric cancer cell lines BGC823 and
AGS, we performed proliferation assays with 48-hour
exposure to RAD001. As a result, RAD001 generates
significant inhibition on both cell lines in a dose-depen-
dent manner. (Figure 3A).
Western blot experiments were performed with
RAD001 at 0, 5, 10, 20 μMf o r4 8h .P 7 0 s 6k i n a s ei sa n
important downstream target of mTOR and its mTOR-
dependent phosphorylation allows translation of riboso-
mal proteins. We examined the phosphorylation status
of downstream target p70s6K by immunoblotting. As
shown in Figure 3B, we found that treatment of both
cell lines BGC823 and AGS with RAD001 significantly
prevent phosphorylation of p70s6K in a dose-dependent
manner.
RAD001 induces G0/G1 cell cycle arrest and apoptosis in
gastric cancer cells
To determine if the suppression in cell proliferation
were due to G0/G1-phase arrest or apoptosis, cell-cycle
distribution was analyzed by FCM. Figure 4 showed that
treatment of BGC823 cells of with RAD001 for 48 hours
resulted in a robust G1 arrest and promoted apoptosis.
With the increasing dose of RAD001, more and more
cells remained in G1-phase, while cell cycle progression
into S phase was decreasing (Figure 4A). RT-PCR analy-
sis revealed RAD001 dose-dependently decreased the
mRNA level of Cyclin D1 and C-myc (Figure 4B).
Annexin-V assays showed that RAD001 significantly
induced apoptosis in BGC823 cells. An increase in
apoptosis rate was analyzed by FCM with the increase
of the dose (Figure 4C). Western blot analysis showed
RAD001 dose-dependently decreasing the protein level
of Bcl-2 and increasing the protein level of p53 (Figure
4D). Similar results were observed in AGS cells (data
not shown).
Discussion
The mammalian target of rapamycin (mTOR) was dis-
covered in the early 1990 s in studying the mechanism
of action of rapamycin, which was originally found as an
antifungal agent and was later recognized as anticancer
properties [27]. As a Ser/Thr protein kinase, mTOR
plays a key role in cellular growth and homeostasis [28].
Table 1 Clinicopathologic correlation of p-mTOR
expression in gastric cancer
Factors All
patients
No. of patients (%) P
N = 181
(%)
mTOR
negative
mTOR
positive
Age(y) .256
< 60 95(52.5) 50(56.8) 45(48.4)
≥60 86(47.5) 38(43.2) 48(51.6)
Sex .926
Male 129(71.3) 63(71.6) 66(71.0)
Female 52(28.7) 25(28.4) 27(29.0)
Site .053
Upper 77(42.5) 33(37.5) 44(47.3)
Middle 28(15.5) 10(11.4) 18(19.4)
lower 74(40.9) 43(48.9) 31(33.3)
Diffuse 2(1.1) 2(2.3) 0(0.0)
Tumor size .172
≤ 4 cm 63(34.8) 35(40.0) 28(30.1)
> 4 cm 118(65.2) 53(60.0) 65(69.9)
Borrmann type .398
Early stage 7(3.9) 6(6.8) 1(1.1)
I 4(2.2) 2(2.3) 2(2.1)
II 65(35.9) 31(35.2) 34(36.6)
III 101(55.8) 47(53.4) 54(58.1)
IV 4(2.2) 2(2.3) 2(2.1)
grading .999
1 4(2.2) 2(2.3) 2(2.1)
2 55(30.4) 27(30.7) 28(30.1)
3 116(64.1) 56(63.6) 60(64.5)
4 6(3.3) 3(3.4) 3(3.3)
Pathologic T
classification
.168
T1 17(9.4) 12(13.6) 5(5.4)
T2 35(19.3) 18(20.5) 17(18.3)
T3 119(65.7) 55(62.5) 64(68.8)
T4 10(5.5) 3(3.4) 7(7.5)
Pathologic N status .008
N negative 44(24.3) 29(33.0) 15(16.1)
N positive 137(75.7) 59(67.0) 78(83.9)
Pathologic stage
(pTNM)
.026
I 26(14.4) 17(19.3) 9(9.7)
II 47(26.0) 28(31.8) 19(20.4)
III 100(55.2) 41(46.5) 59(63.4)
IV 8(4.4) 2(2.3) 6(6.5)
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teins, mTORC1 (mammalian target of rapamycin com-
plex 1) and mTORC2. Activation of mTORC1 regulates
cell growth by modulating protein synthesis, ribosome
biogenesis and autophagy [29]. The mTORC2 pathway
plays a key part of activating Akt, like PDK1(3-phos-
phoinositide-dependent protein kinase 1) and PI3K, a
potential drug target for cancers in which there is Akt
deregulation [26].
In the current study, we observed that 93 (51.4%)
patients had positive expression of p-mTOR in 181 gas-
tric cancer patients. Consistent with our result, in
another study including 1072 patients, the expression of
p-mTOR is 46.5% [30].
Previous studies have reported the prognostic signifi-
cance of p-mTOR expression. Herberger et al [18]. iden-
tified p-mTOR to be an independent prognostic factor
for death in patients with biliary tract adenocarcinoma.
In their study, overall survival was significantly shorter
in patients with p-mTOR-positive tumors as compared
with patients with p-mTOR-negative tumors (P = .004).
In gastric cancer, Yu et al. evaluated expression of p-
mTOR in 1,072 gastric cancer patients using a tissue
microarray, demonstrating overexpression of p-mTOR
was an independent prognostic factor [30]. However, in
a study included 109 patients with gastric adenocarcino-
mas who underwent a radical gastrectomy [31], Mur-
ayama et al. found neither cytoplasmic p-mTOR nor
nuclear p-mTOR was independent prognostic factor,
although they identified cytoplasmic p-mTOR expres-
sion was associated with poorer survival and correlated
with the depth of tumour invasion, lymph nodes and
tumour stage. In the present study, we confirmed that
pT classification and lymph node status are independent
prognostic indicator of clinical outcome in gastric can-
cer patients by multivariable analyses. However, because
most patients present with locally advanced disease,
other secondary prognostic markers, particularly
Figure 1 Examples of p-mTOR immunostaining. (A) The normal gastric mucosa is negative for p-mTOR (original magnification ×200). (B) The
normal gastric mucosa is negative for p-mTOR (original magnification ×400) (C) Positive expression of p-mTOR in gastric cancer (original
magnification ×200). (D) Negative expression of p-mTOR in gastric cancer (original magnification ×200).
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Page 5 of 10p-mTOR, may be of use [13]. Our results clearly show
that p-mTOR expression is correlated strongly with
poor overall and disease-free survival in univariable ana-
lyses with a trend toward correlation in multivariable
analyses.
Consistent with our current study, several studies have
also recognized the antiproliferative effects of mTOR
inhibitors in gastric cancer cells. For example, Lang et al
[21]. identified rapamycin could inhibit gastric cancer
cell growth in both a subcutaneous tumor model and in
an experimental model. Their results highlight the suit-
ability of mTOR inhibitors to be used in an antiangio-
genic context for therapy of gastric cancer.
However, RAD001 is a new mTOR inhibitor as antic-
ancer agent. The mechanism about RAD001 in gastric
cancer is not clear. Cejka et al. showed the antiangio-
genic activity of RAD001 combined with a high dose of
cyclophosphamide revealed synergistic antitumor activity
against gastric cancer [32]. They have also found that
RAD001 decreased proliferation and attenuated produc-
tion of HIF-1a as well as VEGF in gastric cancer cells
in vitro [33]. In the current study, our data showed that
RAD001-therapy attenuated phosphorylation of p70S6K
and markedly inhibited the proliferation of gastric
cancer cells through cell-cycle arrest and apoptosis in
vitro. We found RAD001 induced the G0/G1 phase
arrest, which was associated with decreased cyclin D1
and C-myc. Moreover, we showed for the first time that
RAD001 as a new mTOR inhibitor dose-dependently
induced apoptosis in gastric cancer cells by Annexin V
assays. This effect may be dictated by the cellular con-
text and downstream targets including P53 and Bcl-2.
These findings might further explain the efficacy of
RAD001.
Conclusion
In summary, we conducted systematical research to
mTOR in gastric cancer, indicating the relationships the
expression with the prognosis value of activated mTOR
(p-mTOR) in vivo, the effect of RAD001 and the part of
mechanisms in gastric cancer cells in vitro. Our findings
indicated that p-mTOR would serve as a potential biolo-
gical marker to identify a subgroup of gastric cancer
patients of poor prognosis. It also showed that RAD001
was a promising agent for the treatment of gastric can-
cer with inducing cell cycle arrest and apoptosis by
down-regulating expression of C-myc, CyclinD1 and
Bcl-2, up-regulating expression of P53. Further studies
Table 2 Univariable analysis of disease-free and overall survival in gastric cancer
Disease-free suivival Overall survival
Characteristic No. HR 95%CI p HR 95%CI p
Age(y) .343 .583
< 60 95 1.00 1.00
≥60 86 0.834 0.573-1.214 0.898 0.611-1.320
Sex .662 .950
Male 129 1.00 1.00
Female 52 0.909 0.591-1.396 0.986 0.639-1.521
Tumor size .151 .232
≤4 cm 63 1.00 1.00
> 4 cm 118 1.345 0.897-2.016 1.287 0.851-1.945
pT stage .001 .005
pT1 17 1.00 1.00
pT2 35 1.549 0.558-4.301 .401 1.535 0.553-4.264 .411
pT3 119 3.546 1.437-8.750 .006 3.237 1.310-8.001 .011
pT4 10 4.738 1.547-14.506 .006 4.068 1.289-12.836 .017
pN stage < .0001 .001
Negative 44 1.00 1.00
Positive 137 2.617 1.538-4.451 2.389 1.401-4.075
pTNM stage < .0001 .001
I 26 1.00 1.00
II 47 2.920 1.197-7.121 .018 2.860 1.173-6.973 .021
III 100 4.955 2.152-11.409 < .0001 4.455 1.930-10.281 < .0001
IV 8 7.369 2.470-21.981 < .0001 6.103 1.965-18.957 .002
p-mTOR .008 .013
Negative 88 1.00 1.00
Positive 93 1.667 1.146-2.454 1.644 1.112-2.430
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Page 6 of 10Figure 2 Kaplan-Meier estimates of the probability of survival. Patients with p-mTOR positive showed significantly shorter overall survival (A)
and disease-free survival (B) rates than those with p-mTOR negative expression. (p = .011 and p = .006, respectively).
Table 3 Multivariable cox regression analysis of disease-free and overall survivals
Disease-free suivival Overall survival
Factors No. HR 95%CI p HR 95%CI p
p-mTOR 0.059 0.070
Negative 88 1.00 1.00
Positive 93 1.452 0.986-2.138 1.443 0.970-2.147
Infiltrating depth 0.018 0.046
pT1 17 1.00 1.00
pT2 35 1.050 0.366-3.016 0.928 1.078 0.375-3.101 0.889
pT3 119 2.251 0.867-5.845 0.096 2.146 0.823-5.595 0.118
pT4 10 2.926 0.920-9.305 0.069 2.616 2.616-8.580 0.113
Lymph node status 0.018 0.038
Negative 44 1.00 1.00
Positive 137 1.981 1.981-3.488 1.828 1.034-3.233
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Page 7 of 10Figure 3 (A) RAD001 inhibits proliferation of gastric cancer cells. Gastric cancer cells were treated with the indicated concentrations of
RAD001 in the presence of 10% FBS for 48 h. Cell viability was assessed by MTT assay. (B) Phosphorylation of p70s6K was significantly decreased
in a dose-dependent manner in both AGS and BGC823 cells by the treatment with RAD001. Both cell lines were incubated with increasing dose
of RAD001 for 48 hrs, cell lysates were subjected to western blot analysis with phosphorylated p-S6K and S6K antibodies.
Figure 4 RAD001 induces cell cycle arrest and apoptosis in BGC823 cells. (A) BGC823 cells were exposed to various concentrations of
RAD001 for 48 h. (B) RNA were extracted from cells. Cyclin D1 and C-myc expression level were detected by RT-PCR, actin as a loading control.
(C) cells were incubated for 48 hrs with indicated doses of RAD001 before staining with annexin V-FITC. The percentages of apoptotic cells are
displayed. (D) Cells were incubated for 48 hrs with indicated doses of RAD001. Cells were collected, lysed and subjected to Western blot analysis
with Bcl-2 and p53 antibodies. GAPDH was used as a loading control.
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Page 8 of 10are required to elucidate the role of the activation of
mTOR and eventually to propose mTOR as a concrete
target for gastric cancer therapy.
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